The US subsidiary of the Indian pharma company Lupin has acquired Symbiomix Therapeutics, a privately held company focused on the development of products to treat gynecologic infections that can have serious health consequences. According to the company, the deal accounted for $ 150 million including a $ 50 million upfront and other time-based payments. The acquisition of Symbiomix and the Solosec™ franchise significantly expands Lupin’s branded women’s health specialty business, which is presently anchored by methylergonovine tablets.